Cathy Quelen
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas.
Journal: Leukemia
Published: January 13, 2026
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.
Journal: Journal for immunotherapy of cancer
Published: October 04, 2023
Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR.
Journal: The Journal of molecular diagnostics : JMD
Published: May 12, 2020
PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 28, 2018
miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
Journal: Haematologica
Published: April 09, 2018
Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells.
Journal: Oncotarget
Published: November 11, 2017
MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors.
Journal: The Journal of pathology
Published: July 18, 2016
Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia.
Journal: British journal of haematology
Published: June 23, 2015
RNA editing in acute myeloid leukaemia with normal karyotype.
Journal: British journal of haematology
Published: June 01, 2015
Key contribution of eIF4H-mediated translational control in tumor promotion.
Journal: Oncotarget
Published: May 27, 2015
Last Updated: 09/26/2026